Literature DB >> 30593536

Human Anti-HIV-1 gp120 Monoclonal Antibodies with Neutralizing Activity Cloned from Humanized Mice Infected with HIV-1.

Melissa A Gawron1, Mark Duval1, Claudia Carbone2, Smita Jaiswal2, Aaron Wallace1, Joseph C Martin1, Ann Dauphin2, Michael A Brehm2, Dale L Greiner2, Leonard D Shultz3, Jeremy Luban2, Lisa A Cavacini4.   

Abstract

Broadly neutralizing, anti-HIV-1 gp120 mAbs have been isolated from infected individuals, and there is considerable interest in developing these reagents for Ab-based immunoprophylaxis and treatment. As a means to identify potentially new anti-HIV Abs, we exploited humanized NOD-scid IL2rγnull mice systemically infected with HIV-1 to generate a wide variety of Ag-specific human mAbs. The Abs were encoded by a diverse range of variable gene families and Ig classes, including IgA, and several showed significant levels of somatic mutation. Moreover, the isolated Abs not only bound target Ags with similar affinity as broadly neutralizing Abs, they also demonstrated neutralizing ability against multiple HIV-1 clades. The use of humanized mice will allow us to use our knowledge of HIV-1 gp120 structure and function, and the immune response targeting this protein, to generate native human prophylactic Abs to reduce the infection and spread of HIV-1.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30593536      PMCID: PMC6344273          DOI: 10.4049/jimmunol.1801085

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Authors:  Timothy Fouts; Karla Godfrey; Kathryn Bobb; David Montefiori; Carl V Hanson; V S Kalyanaraman; Anthony DeVico; Ranajit Pal
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

Review 2.  Humanized mice for immune system investigation: progress, promise and challenges.

Authors:  Leonard D Shultz; Michael A Brehm; J Victor Garcia-Martinez; Dale L Greiner
Journal:  Nat Rev Immunol       Date:  2012-10-12       Impact factor: 53.106

3.  Generation of human antigen-specific monoclonal IgM antibodies using vaccinated "human immune system" mice.

Authors:  Pablo D Becker; Nicolas Legrand; Caroline M M van Geelen; Miriam Noerder; Nicholas D Huntington; Annick Lim; Etsuko Yasuda; Sean A Diehl; Ferenc A Scheeren; Michael Ott; Kees Weijer; Heiner Wedemeyer; James P Di Santo; Tim Beaumont; Carlos A Guzman; Hergen Spits
Journal:  PLoS One       Date:  2010-10-04       Impact factor: 3.240

4.  Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.

Authors:  Rebecca M Lynch; Eli Boritz; Emily E Coates; Adam DeZure; Patrick Madden; Pamela Costner; Mary E Enama; Sarah Plummer; Lasonji Holman; Cynthia S Hendel; Ingelise Gordon; Joseph Casazza; Michelle Conan-Cibotti; Stephen A Migueles; Randall Tressler; Robert T Bailer; Adrian McDermott; Sandeep Narpala; Sijy O'Dell; Gideon Wolf; Jeffrey D Lifson; Brandie A Freemire; Robert J Gorelick; Janardan P Pandey; Sarumathi Mohan; Nicolas Chomont; Remi Fromentin; Tae-Wook Chun; Anthony S Fauci; Richard M Schwartz; Richard A Koup; Daniel C Douek; Zonghui Hu; Edmund Capparelli; Barney S Graham; John R Mascola; Julie E Ledgerwood
Journal:  Sci Transl Med       Date:  2015-12-23       Impact factor: 17.956

5.  Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.

Authors:  Katharine J Bar; Michael C Sneller; Linda J Harrison; J Shawn Justement; Edgar T Overton; Mary E Petrone; D Brenda Salantes; Catherine A Seamon; Benjamin Scheinfeld; Richard W Kwan; Gerald H Learn; Michael A Proschan; Edward F Kreider; Jana Blazkova; Mark Bardsley; Eric W Refsland; Michael Messer; Katherine E Clarridge; Nancy B Tustin; Patrick J Madden; KaSaundra Oden; Sijy J O'Dell; Bernadette Jarocki; Andrea R Shiakolas; Randall L Tressler; Nicole A Doria-Rose; Robert T Bailer; Julie E Ledgerwood; Edmund V Capparelli; Rebecca M Lynch; Barney S Graham; Susan Moir; Richard A Koup; John R Mascola; James A Hoxie; Anthony S Fauci; Pablo Tebas; Tae-Wook Chun
Journal:  N Engl J Med       Date:  2016-11-09       Impact factor: 91.245

6.  Antibody repertoires in humanized NOD-scid-IL2Rγ(null) mice and human B cells reveals human-like diversification and tolerance checkpoints in the mouse.

Authors:  Gregory C Ippolito; Kam Hon Hoi; Sai T Reddy; Sean M Carroll; Xin Ge; Tobias Rogosch; Michael Zemlin; Leonard D Shultz; Andrew D Ellington; Carla L Vandenberg; George Georgiou
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

7.  Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject.

Authors:  Liuzhe Li; Xiao-Hong Wang; Sagarika Banerjee; Barbara Volsky; Constance Williams; Diana Virland; Arthur Nadas; Michael S Seaman; Xuemin Chen; Paul Spearman; Susan Zolla-Pazner; Miroslaw K Gorny
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

Review 8.  IgG subclasses and allotypes: from structure to effector functions.

Authors:  Gestur Vidarsson; Gillian Dekkers; Theo Rispens
Journal:  Front Immunol       Date:  2014-10-20       Impact factor: 7.561

9.  Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy.

Authors:  Rafiq Nabi; Zina Moldoveanu; Qing Wei; Elizabeth T Golub; Helen G Durkin; Ruth M Greenblatt; Betsy C Herold; Marek J Nowicki; Seble Kassaye; Michael W Cho; Abraham Pinter; Alan L Landay; Jiri Mestecky; Pamela A Kozlowski
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240

10.  Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development.

Authors:  Kevin Wiehe; Todd Bradley; R Ryan Meyerhoff; Connor Hart; Wilton B Williams; David Easterhoff; William J Faison; Thomas B Kepler; Kevin O Saunders; S Munir Alam; Mattia Bonsignori; Barton F Haynes
Journal:  Cell Host Microbe       Date:  2018-05-31       Impact factor: 31.316

View more
  3 in total

1.  Repertoire characterization and validation of gB-specific human IgGs directly cloned from humanized mice vaccinated with dendritic cells and protected against HCMV.

Authors:  Sebastian J Theobald; Christoph Kreer; Sahamoddin Khailaie; Agnes Bonifacius; Britta Eiz-Vesper; Constanca Figueiredo; Michael Mach; Marija Backovic; Matthias Ballmaier; Johannes Koenig; Henning Olbrich; Andreas Schneider; Valery Volk; Simon Danisch; Lutz Gieselmann; Meryem Seda Ercanoglu; Martin Messerle; Constantin von Kaisenberg; Torsten Witte; Frank Klawonn; Michael Meyer-Hermann; Florian Klein; Renata Stripecke
Journal:  PLoS Pathog       Date:  2020-07-15       Impact factor: 6.823

2.  Preparation and characterization of monoclonal antibodies recognizing two CD4 isotypes of Microminipigs.

Authors:  Shino Ohshima; Tatsuya Matsubara; Asuka Miyamoto; Atsuko Shigenari; Noriaki Imaeda; Masaki Takasu; Masafumi Tanaka; Takashi Shiina; Shingo Suzuki; Noriaki Hirayama; Hitoshi Kitagawa; Jerzy K Kulski; Asako Ando; Yoshie Kametani
Journal:  PLoS One       Date:  2020-11-25       Impact factor: 3.240

Review 3.  Humanized Mice as an Effective Evaluation System for Peptide Vaccines and Immune Checkpoint Inhibitors.

Authors:  Yoshie Kametani; Yusuke Ohno; Shino Ohshima; Banri Tsuda; Atsushi Yasuda; Toshiro Seki; Ryoji Ito; Yutaka Tokuda
Journal:  Int J Mol Sci       Date:  2019-12-16       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.